Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|1|40-49

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.1, 2015-07, pp. : 40-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : 417-421

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 5, 2015-11 ,pp. : 1001-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 33-40

John Wiley & Sons Inc

Access to resources Recommend Favorite

The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 7-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival outcomes and treatment costs for patients with double‐refractory chronic lymphocytic leukaemia (DR‐CLL)

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 3, 2015-05 ,pp. : 449-452

John Wiley & Sons Inc

Access to resources Recommend Favorite